Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Disease: A Cost-Effectiveness Analysis in a Simulated Cohort

BACKGROUND: Therapeutic drug monitoring (TDM) is increasingly performed for Infliximab (IFX) in patients with Crohn’s disease (CD). Reactive TDM is a cost-effective strategy to empiric IFX dose escalation. The cost-effectiveness of proactive TDM is unknown. The aim of this study is to assess the cos...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Inflamm Bowel Dis
Glavni autori: Negoescu, Diana M, Enns, Eva A, Swanhorst, Brooke, Baumgartner, Bonnie, Campbell, James P, Osterman, Mark T, Papamichael, Konstantinos, Cheifetz, Adam S, Vaughn, Byron P
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Original Clinical Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6905301/
https://ncbi.nlm.nih.gov/pubmed/31184366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ibd/izz113
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items